Guardant Health, Inc. reported total revenue of $232.1 million for the second quarter of 2025, a 31% increase from $177.2 million in the corresponding prior year period. The company's net loss was $99.9 million, or $0.80 per share, with a non-GAAP net loss of $55.0 million, or $0.44 per share.
The company raised its full-year 2025 revenue guidance for the second time this year, now expecting a range of $915 million to $925 million, representing 24% to 25% growth over 2024. This is an increase from the prior range of $880 million to $890 million.
Oncology revenue grew 22% to $158.7 million, driven by a 30% surge in oncology test volume. Screening revenue from the Shield test totaled $14.8 million from approximately 16,000 tests, with non-GAAP gross margin significantly improving to 48%. Non-GAAP gross margin for the company reached 66%, up from 60% in Q2 2024. The company continues to expect free cash flow burn of $225 million to $235 million, with the core business (excluding screening) on track to reach free cash flow breakeven in Q4 2025.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.